You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Patent: 4,614,719


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,614,719
Title: Process for producing ribavirin
Abstract:There is disclosed a process for producing ribavirin from 1,2,4-triazole-carboxamide and a ribose donor by the enzymatic action of a microorganism belonging to specific genera, e.g. Brevebacterium. The specific feature of the invention is, above all, utilization of said microorganism under non-proliferatating conditions.
Inventor(s): Fujishima; Tetsuro (Choshi, JP), Yamamoto; Yoshiomi (Choshi, JP)
Assignee: Yamasa Shoyu Kabushiki Kaisha (Chiba, JP)
Application Number:06/489,409
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

The Patent Landscape and Critical Analysis of US Patent 4,614,719

Introduction

The United States patent system is a complex and evolving field, particularly when it comes to the validation and challenges of patents. This article will delve into the broader patent landscape, focusing on the mechanisms for challenging patents, the criteria for patentability, and a critical analysis of a specific patent, US Patent 4,614,719.

The Patent Trial and Appeal Board (PTAB) and Inter Partes Review

The Leahy-Smith America Invents Act (AIA) of 2011 introduced significant changes to U.S. patent law, notably the creation of the Patent Trial and Appeal Board (PTAB) within the U.S. Patent and Trademark Office (USPTO). PTAB is empowered to hear administrative challenges to the validity of previously granted patents through Inter Partes Review (IPR) and Post-Grant Review (PGR)[1].

Advantages of PTAB Proceedings

For entities facing patent infringement claims, PTAB proceedings offer several advantages over judicial proceedings. These include faster resolution times, lower costs, and a lower burden of proof to invalidate patents. This makes PTAB a preferred route for challenging patent validity[1].

Patentability Requirements

To be granted, a patent must meet several criteria:

  • Eligible Subject Matter: The invention must fall within the categories of "process, machine, manufacture, or composition of matter, or any improvement thereof." However, laws of nature, natural phenomena, and abstract ideas are not patentable[1].
  • Novelty: The claimed invention must be new and not previously disclosed in the prior art[1].
  • Nonobviousness: The invention must be significantly different from existing knowledge and not obvious to a person of ordinary skill in the relevant field[1].

Subject Matter Eligibility Under 35 U.S.C. ยง 101

The subject matter eligibility test, as outlined in the Alice/Mayo framework, is a two-step process:

  • Step 1: Determine if the claim is directed to an abstract idea, law of nature, or natural phenomenon.
  • Step 2A: If so, assess whether the claim contains an "inventive concept" that transforms the nature of the claim into a patent-eligible application. This often involves demonstrating a specific, concrete technological advancement or solution to a technical problem[2].

Practical Applicability Analysis

The 2024 Guidance Update emphasizes the importance of Prong Two of Step 2A, which involves showing that the claims are directed to a specific technological improvement. For AI inventions, this might involve demonstrating improvements in computer functionality or other technical fields. The argument must be clear and focused to persuade the patent examiner effectively[2].

Cybersecurity Innovations and Patent Landscape

The cybersecurity sector has seen a significant increase in patent applications over the past two decades. The U.S. leads in cybersecurity patent filings, with over 1,087 patents filed since 2000. This reflects the growing need for innovative solutions to combat cyber attacks, which have become more sophisticated and frequent[3].

Analysis of US Patent 4,614,719

Background

US Patent 4,614,719, while not specifically detailed in the provided sources, can be analyzed within the context of the broader patent landscape.

Eligibility and Patentability

To critically analyze this patent, one must first determine if it meets the eligibility and patentability criteria:

  • Subject Matter Eligibility: Does the patent claim fall within the eligible categories? If it involves abstract ideas or laws of nature, does it contain an "inventive concept" that makes it patent-eligible?
  • Novelty and Nonobviousness: Was the invention new and not obvious at the time of filing? A thorough review of prior art would be necessary to assess this.

Challenges and Validity

Given the PTAB's role in challenging patents, any analysis of US Patent 4,614,719 should consider whether it could withstand an IPR or PGR. This involves examining the patent's claims in light of the Alice/Mayo framework and other patentability requirements.

Case Studies and Industry Trends

In the context of cybersecurity, for example, patents must often demonstrate significant technological advancements. If US Patent 4,614,719 relates to a technological field such as cybersecurity, it would need to show how it improves existing solutions or addresses specific technical problems[3].

Practical Considerations for Patent Holders

For patent holders, understanding the PTAB's processes and the subject matter eligibility analysis is crucial. This includes being prepared to argue the practical applicability of their inventions and demonstrating how they improve existing technologies[2].

International Patent Landscape

The global patent landscape is competitive, with countries like the U.S., China, and those in Europe actively filing and protecting patents. International patent applications under the Patent Cooperation Treaty (PCT) provide worldwide protection, which is essential for inventions with global implications[3].

Challenges in Patent Examination

Patent examiners often face challenges in applying the subject matter eligibility framework consistently. Applicants must be aware of these inconsistencies and craft arguments that are persuasive to the examiners, who may have limited time and attention to review each response thoroughly[2].

Key Takeaways

  • PTAB and IPR: The PTAB plays a critical role in challenging patent validity, offering faster and less expensive alternatives to judicial proceedings.
  • Patentability Requirements: Patents must meet eligibility, novelty, and nonobviousness criteria to be granted.
  • Subject Matter Eligibility: The Alice/Mayo framework is crucial for determining patent eligibility, especially for AI and technological inventions.
  • Cybersecurity Innovations: The cybersecurity sector is highly active in patent filings, reflecting the need for innovative solutions.
  • Global Patent Landscape: The U.S., China, and Europe are key players in the global patent landscape, with international applications providing broad protection.

FAQs

Q: What is the role of the Patent Trial and Appeal Board (PTAB) in the U.S. patent system? A: The PTAB is responsible for hearing administrative challenges to the validity of previously granted patents through Inter Partes Review (IPR) and Post-Grant Review (PGR).

Q: How does the Alice/Mayo framework impact patent eligibility? A: The Alice/Mayo framework is a two-step process that determines if a patent claim is directed to an abstract idea, law of nature, or natural phenomenon, and if it contains an "inventive concept" that makes it patent-eligible.

Q: Why is the cybersecurity sector seeing an increase in patent applications? A: The rise in cybersecurity patent applications is driven by the increasing need for innovative solutions to combat sophisticated cyber attacks.

Q: What are the advantages of using PTAB proceedings over judicial proceedings for challenging patents? A: PTAB proceedings are generally faster, less expensive, and require a lower burden of proof to invalidate patents.

Q: How does the global patent landscape affect patent holders? A: The global patent landscape requires patent holders to consider international protection through mechanisms like the Patent Cooperation Treaty (PCT) to safeguard their intellectual property worldwide.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Baker Botts, "The Importance of Prong Two of Step 2A for AI Inventions," September 2024.
  3. IS Decisions, "Cybersecurity Innovations And The Patent Landscape," November 21, 2023.

More… ↓

⤷  Subscribe

Details for Patent 4,614,719

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 June 04, 2004 ⤷  Subscribe 2003-09-30
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 June 13, 2008 ⤷  Subscribe 2003-09-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.